# Applying fair-treatment and non-discrimination rules to patient marketing
A billboard reads: "Same-day joint replacement. Private suites. Concierge scheduling." It runs only in three affluent ZIP codes. The hospital's lawyers never saw it. Six months later, a civil rights complaint alleges the campaign steered high-margin orthopedic patients away from lower-income neighborhoods that the hospital is obligated to serve. The marketing team thought they were doing their job. They were also creating regulatory exposure.
In healthcare, marketing is not a free space. Three overlapping US rules (EMTALA, ACA Section 1557, and IRS financial-assistance transparency requirements) directly shape what a hospital can promote, to whom, and how. This lesson walks through each and shows where the marketing decision actually happens.
EMTALA (the Emergency Medical Treatment and Labor Act, 1986) requires any hospital with an emergency department that accepts Medicare to screen and stabilize anyone who arrives with an emergency, regardless of ability to pay or insurance status.
Why does an emergency-care law matter to marketing? Because your messaging cannot contradict the obligation.
Concrete traps:
The marketing fix is language discipline. Any emergency-service promotion should avoid payment gating, and financial information near the ED should follow EMTALA-safe wording (screening first, billing conversations later). The CMS EMTALA overview is the authoritative free reference.
Section 1557 of the Affordable Care Act (2010) is the core non-discrimination rule for health programs receiving federal funds. It prohibits discrimination based on race, color, national origin, sex, age, and disability.
For marketing, two dimensions matter most.
1. Language access. National origin protection means people with Limited English Proficiency (LEP) must be able to access your communications. Practically:
2. Disability access. Your website, patient portal, and digital ads should be accessible (screen-reader compatible, captioned video, adequate contrast). An orthopedic microsite that a blind patient cannot navigate is both a marketing failure and a 1557 exposure.
3. Sex and the targeting question. 1557's sex-discrimination provisions have shifted with successive administrations and litigation. As of 2026, the exact scope (including gender identity) has moved through rulemaking and court challenges, so treat the precise boundaries as unsettled and check current HHS Office for Civil Rights guidance rather than relying on a fixed rule.
The subtler marketing risk is targeting itself. Digital ad platforms let you segment by ZIP, inferred income, device, and behavior. Section 1557 concerns arise when segmentationsegmentationDividing a market into distinct groups of customers who share similar needs, characteristics or behaviours, so each group can be served with a tailored approach.Voir la définition complète → produces a discriminatory effect: systematically excluding protected populations from awareness of a service they are eligible for.
Non-profit hospitals (most US hospitals) must comply with Internal Revenue Code Section 501(r) to keep their tax-exempt status. Among other things, 501(r) requires them to:
"Widely publicize" is a marketing verb. It typically means the FAP and a plain-language summary must be on the website, offered in the languages of significant populations served, and visible in the facility. If your slick service-line campaigns are everywhere but your charity-care information is buried three clicks deep, that gap is exactly what regulators and journalists look for.
The IRS 501(r) requirements page is the primary free source.
Service lines (bundled offerings like cardiac, orthopedics, maternity, oncology) are the most heavily marketed and the highest margin. That is precisely where fair-treatment risk concentrates.
Ask three questions before launch:
1. Does the geographic or demographic targeting exclude protected populations who are clinically eligible?
2. Does the creative imply access is conditional on insurance or payment (EMTALA-adjacent tone)?
3. Are LEP and disabled patients able to receive and act on this message?
Example: a maternity campaign is fine. A maternity campaign placed only in high-income ZIPs, English-only, with imagery of a single demographic, in a diverse service area, is a pattern that invites scrutiny.
Treat the FAP like a product you must actively market, not a compliance PDF.
Good practice:
Outreach *toward* underserved groups (for example, a diabetes screening drive in an underserved neighborhood) is generally encouraged and supports community-benefit obligations. The line to watch: use protected-class information to *include and serve*, not to *exclude or upsell selectively*.
🎬 [VIDEO: "Section 1557 Nondiscrimination Basics" - youtube.com - a short plain-language explainer on the ACA's core non-discrimination provisions for health programs]
Build a lightweight gate every campaign passes before spend. A practical checklist:
If you run programmatic ad audiences, keep an auditable record of exclusions. A one-line log per campaign is enough to show intent:
campaign: ortho_q1_2026
audience_included: metro_service_area_all_zips
audience_excluded: none
lep_taglines: es, zh
accessibility_check: pass (2026-01-14)
reviewer: compliance_jdoeThat record is your defense if a targeting question ever arises. "We deliberately did not exclude" is a strong position; silence is not.
Vérification des acquis
1. The billboard example (same-day joint replacement ads placed only in affluent ZIP codes) illustrates which core regulatory risk in patient marketing?
2. Why does EMTALA, an emergency-care statute, constrain a hospital's marketing rather than only its clinical operations?
3. A hospital wants to post signage near its ED about billing and financial policies. Which approach is most consistent with EMTALA-safe messaging?
4. Select ALL correct answers. Which of the following marketing practices could create EMTALA-related exposure?
Sélectionnez toutes les réponses correctes.
5. Select ALL correct answers. What does the billboard scenario reveal about how marketing decisions and compliance interact in healthcare?
Sélectionnez toutes les réponses correctes.
Regulators and plaintiffs rarely start with your intentions. They start with your *artifacts*: the billboard, the ad-platform audience settings, the buried FAP link, the English-only microsite. Marketing produces most of the evidence in a fair-treatment dispute.
Two enforcement channels to know:
Reputational cost usually exceeds the legal cost. Investigative reporting on hospitals suing low-income patients while promoting premium suites has repeatedly damaged brands. The marketing team owns that contrast whether or not it wrote both messages.
A note on Europe for context: the EU does not have EMTALA or 501(r) equivalents, but healthcare advertising is constrained by national medical-advertising rules and by GDPR (the General Data Protection Regulation), which treats health data as a special category. Targeting European patients using inferred health status carries strict consent requirements. The mechanics differ; the principle (do not let targeting become discrimination or covert profiling) rhymes.